TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Steve Hood
Director, Bioimaging and D@T at GlaxoSmithKline

Profile

Steve studied for his PhD in Molecular Toxicology at Surrey University and joined Glaxo Group Research as a Post-Doctoral Fellow in 1993. Following the formation of GSK in 2001, Steve managed a team determining the drug-drug interaction liabilities while developing ADME strategies for the emerging GSK antibody portfolio.

In 2010, Steve led a cross divisional team charged with understanding and overcoming the delivery issues inherent in GSK’s diverse oligonucleotide portfolio while helping to develop these molecules from early discovery to file. In 2011 Steve initiated a project that has grown into the active IMI academic/Industry COMPACT collaboration  (http://www.compact-research.org/) and he is actively involved in facilitating the interaction between academia , biotech and large industry partners.

Finally, for the past couple of years, Steve has been responsible for helping GSK Programme teams explore “Where does my drug go and what does it do when it gets there?” using a range of Bioimaging methodologies. He is the Co-Director of the GSK Centre for Optical Molecular Imaging at the University of Illinois at Urbana Champaign and the custodian of the GSK Bioimaging Expertise network.


Steve holds Fellowships with the Royal Society of Biology, the DMDG and is a Senior GSK Fellow

Steve Hood's Network

Agenda Sessions

  • Applying New Imaging Modalities to the ADME of ASO and Peptide Drugs

    , 11:00
  • Applying New Imaging Modalities to the ADME of ASO and Peptide Drugs

    , 11:00
  • Applying New Imaging Modalities to the ADME of ASO and Peptide Drugs

    , 11:00